Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Amylyx, Astrazeneca, Boehringer Ingelheim, Erasca, Gilead, Intercept, Janssen, Leo, Lianbio, Moderna, Molecure, Pfizer, Sarepta, Zealand.
Enanta Pharmaceuticals Inc. has synthesized spirocyclic compounds acting as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
Having caused over 6.2 million deaths globally ongoing, the COVID-19 pandemic since 2020 continues to pose a serious public health challenge. While the SARS-CoV-2 receptors angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 play requisite roles in permitting the initial infection, up to 10 proviral host factors have also been determined to play crucial roles in controlling the viral replication, but most are not pharmacologically targetable.
The U.S. FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend COVID-19 vaccines for the 2023-2024 vaccination campaign be monovalent vaccines that target the XBB variants, currently the most prominent variants of the SARS-CoV-2 virus.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Astrazeneca, Bloomsbury, Lantern, Merck & Co., Neobiosis, Pharmala, Phathom.